Investigation of a water equivalent depth method for dosimetric accuracy evaluation of synthetic CT.

PURPOSE: To provide a metric that reflects the dosimetric utility of the synthetic CT (sCT) and can be rapidly determined. METHODS: Retrospective CT and atlas-based sCT of 62 (53 IMRT and 9 VMAT) prostate cancer patients were used. For image similarity measurements, the sCT and reference CT (rCT) were aligned using clinical registration parameters. Conventional image similarity metrics including the mean absolute error (MAE) and mean error (ME) were calculated. The water equivalent depth (WED) was automatically determined for each patient on the rCT and sCT as the distance from the skin surface to the treatment plan isocentre at 36 equidistant gantry angles, and the mean WED difference (ΔWED¯) between the two scans was calculated. Doses were calculated on each scan pair for the clinical plan in the treatment planning system. The image similarity measurements and ΔWED¯ were then compared to the isocentre dose difference (ΔDiso) between the two scans. RESULTS: While no particular relationship to dose was observed for the other image similarity metrics, the ME results showed a linear trend against ΔDiso with R2 = 0.6, and the 95 % prediction interval for ΔDiso between -1.2 and 1 %. The ΔWED¯ results showed an improved linear trend (R2 = 0.8) with a narrower 95 % prediction interval from -0.8 % to 0.8 %. CONCLUSION: ΔWED¯ highly correlates with ΔDiso for the reference and synthetic CT scans. This is easy to calculate automatically and does not require time-consuming dose calculations. Therefore, it can facilitate the process of developing and evaluating new sCT generation algorithms.

Voxel-based supervised machine learning of peripheral zone prostate cancer using noncontrast multiparametric MRI.

PURPOSE: The aim of this study was to develop and assess the performance of supervised machine learning technique to classify magnetic resonance imaging (MRI) voxels as cancerous or noncancerous using noncontrast multiparametric MRI (mp-MRI), comprised of T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and advanced diffusion tensor imaging (DTI) parameters. MATERIALS AND METHODS: In this work, 191 radiomic features were extracted from mp-MRI from prostate cancer patients. A comprehensive set of support vector machine (SVM) models for T2WI and mp-MRI (T2WI + DWI, T2WI + DTI, and T2WI + DWI + DTI) were developed based on novel Bayesian parameters optimization method and validated using leave-one-patient-out approach to eliminate any possible overfitting. The diagnostic performance of each model was evaluated using the area under the receiver operating characteristic curve (AUROC). The average sensitivity, specificity, and accuracy of the models were evaluated using the test data set and the corresponding binary maps generated. Finally, the SVM plus sigmoid function of the models with the highest performance were used to produce cancer probability maps. RESULTS: The T2WI + DWI + DTI models using the optimal feature subset achieved the best performance in prostate cancer detection, with the average AUROC , sensitivity, specificity, and accuracy of 0.93 ± 0.03, 0.85 ± 0.05, 0.82 ± 0.07, and 0.83 ± 0.04, respectively. The average diagnostic performance of T2WI + DTI models was slightly higher than T2WI + DWI models (+3.52%) using the optimal radiomic features. CONCLUSIONS: Combination of noncontrast mp-MRI (T2WI, DWI, and DTI) features with the framework of a supervised classification technique and Bayesian optimization method are able to differentiate cancer from noncancer voxels with high accuracy and without administration of contrast agent. The addition of cancer probability maps provides additional functionality for image interpretation, lesion heterogeneity evaluation, and treatment management.

Bulk Anatomical Density Based Dose Calculation for Patient-Specific Quality Assurance of MRI-Only Prostate Radiotherapy.

Prostate cancer treatment planning can be performed using magnetic resonance imaging (MRI) only with sCT scans. However, sCT scans are computer generated from MRI data and therefore robust, efficient, and accurate patient-specific quality assurance methods for dosimetric verification are required. Bulk anatomical density (BAD) maps can be generated based on anatomical contours derived from the MRI image. This study investigates and optimizes the BAD map approach for sCT quality assurance with a large patient CT and MRI dataset. 3D T2-weighted MRI and full density CT images of 54 patients were used to create BAD maps with different tissue class combinations. Mean Hounsfield units (HU) of Fat (F: below -30 HU), the entire Tissue [T: excluding bone (B)], and Muscle (M: excluding bone and fat) were derived from the CT scans. CT based BAD maps (BADBT,CT and BADBMF,CT) and a conventional bone and water bulk-density method (BADBW,CT) were compared to full CT calculations with bone assignments to 366 HU (measured) and 288 HU (obtained from literature). Optimal bulk densities of Tissue for BADBT,CT and Bone for BADBMF,CT were derived to provide zero mean isocenter dose agreement to the CT plan. Using the optimal densities, the dose agreement of BADBT,CT and BADBMF,CT to CT was redetermined. These maps were then created for the MRI dataset using auto-generated contours and dose calculations compared to CT. The average mean density of Bone, Fat, Muscle, and Tissue were 365.5 ± 62.2, -109.5 ± 12.9, 23.3 ± 9.7, and -46.3 ± 15.2 HU, respectively. Comparing to other bulk-density maps, BADBMF,CT maps provided the closest dose to CT. Calculated optimal mean densities of Tissue and Bone were -32.7 and 323.7 HU, respectively. The isocenter dose agreement of the optimal density assigned BADBT,CT and BADBMF,CT to full density CT were 0.10 ± 0.65% and 0.01 ± 0.45%, respectively. The isocenter dose agreement of MRI generated BADBT,MR and BADBMF,MR to full density CT were -0.15 ± 0.90% and -0.16 ± 0.65%, respectively. The BAD method with optimal bulk densities can provide robust, accurate and efficient patient-specific quality assurance for dose calculations in MRI-only radiotherapy.

Evolutionary Wavelet Neural Network ensembles for breast cancer and Parkinson's disease prediction.

Wavelet Neural Networks are a combination of neural networks and wavelets and have been mostly used in the area of time-series prediction and control. Recently, Evolutionary Wavelet Neural Networks have been employed to develop cancer prediction models. The present study proposes to use ensembles of Evolutionary Wavelet Neural Networks. The search for a high quality ensemble is directed by a fitness function that incorporates the accuracy of the classifiers both independently and as part of the ensemble itself. The ensemble approach is tested on three publicly available biomedical benchmark datasets, one on Breast Cancer and two on Parkinson's disease, using a 10-fold cross-validation strategy. Our experimental results show that, for the first dataset, the performance was similar to previous studies reported in literature. On the second dataset, the Evolutionary Wavelet Neural Network ensembles performed better than all previous methods. The third dataset is relatively new and this study is the first to report benchmark results.